Navigation Links
Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting
Date:4/14/2009

DENVER and CAMBRIDGE, Mass., April 14 /PRNewswire/ -- (AACR 100th Annual Meeting 2009) - Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that the results of a joint collaboration with one of its top pharmaceutical partners will be presented at the American Association for Cancer Research's (AACR) 100th Annual Meeting 2009 being held in Denver, Colo. April 18-22, 2009.

Michael Macoritto, Ph.D., project lead/scientist II at Genstruct will be presenting a poster titled, "Causal Reasoning Identifies Mechanisms of Sensitivity for a Novel AKT Kinase Inhibitor: GSK690693" on April 21 from 1:00 - 5:00 p.m. The poster will focus on how Genstruct and its partner evaluated the mechanisms for sensitivity for GSK690693 in six cell cultures and three xenografts from human breast, prostate and ovarian cancer cell lines using Genstruct's Causal Network(TM) modeling platform on RNA expression and phosphoproteomics data.

"This research project is an excellent example of the capabilities of our Causal Network Modeling platform," said Dr. Macoritto. "By using causal modeling, our team of expert scientists was able to demonstrate one of the main tenets of systems biology -- that the networks that regulate cellular processes are conserved across tumor and tissue types, even when the transcriptional responses of these tissues are markedly different."

About Genstruct

Founded in 2002, Genstruct is a systems biology company focused on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. By developing Causal Network(TM) models for complex biological systems, Genstruct develops a deep molecular understanding of diseases and drug action, and designs mechanistic biomarkers and molecular diagnostics to facilitate drug development and personalized medicine. Genstruct's Consulting Services division engages in short-, mid- and long-term partnerships with top tier pharmaceutical and life sciences companies, to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. Genstruct was awarded the Bio-IT World 2008 Best Practices Award in the Drug Discovery & Development category for its joint collaboration with Sirtris Pharmaceuticals (a GSK company). Genstruct is a privately held company based in Cambridge, Mass. For more information, please visit www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Causal Network Model and Knowledge Assembly are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

    Contact:
    Karen Higgins
    A & E Communications for Genstruct
    (610) 831-5723
    khiggins@aandecomm.com


'/>"/>
SOURCE Genstruct
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Genstruct Added to The Biomarker Consortiums Rapidly Growing Roster of Industry Experts
2. Genstruct Expands Team with New VP of Engineering
3. Genstruct Names Louis Latino VP of Sales
4. Genstruct and Sirtris Pharmaceuticals Win Bio-IT Worlds Best Practices Award
5. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
6. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
7. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
8. Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
9. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
10. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
11. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... and NEW YORK , ... Group (SELLAS or the Company), a late-stage biopharmaceutical ... list of cancer indications, today reported updated positive ... treatment, galinpepimut-S, in multiple myeloma (MM) patients. Consistent ... meaningful clinical benefit among high-risk MM patients, positioning ...
(Date:3/1/2017)... 2017 Illustris Pharmaceuticals, Inc. today announced the ... delivery technology platform.  The leadership team consists of ... Prygocki , former President of Medicis, Dr. Jacob ... , founding member of Derma-Rx and IDS Clinic and ... in Asia , and Andrew ...
(Date:3/1/2017)... Fla. , March 1, 2017  Friends, family, ... living with multiple sclerosis (MS), a chronic condition affecting ... MSWorld , MS Views and News , ... the Multiple Sclerosis Foundation — have joined biotechnology ... partners through the #MySupportHero initiative. During MS Awareness Month, ...
(Date:3/1/2017)... ... March 01, 2017 , ... At interpack ... concentrating on protection, productivity and quality can help food and pharmaceutical manufacturers improve ... – from x-ray and checkweighing to vision inspection and metal detection – will ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
Breaking Biology News(10 mins):